Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study

Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study

Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ramadan A, Lagarce F, Tessier-Marteau A, Thomas O, Legras P, Macchi L, Saulnier P, Benoit JP
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/1375d1ca280b41f7b0ea481e1a752324
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1375d1ca280b41f7b0ea481e1a752324
record_format dspace
spelling oai:doaj.org-article:1375d1ca280b41f7b0ea481e1a7523242021-12-02T06:46:36ZOral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study1176-91141178-2013https://doaj.org/article/1375d1ca280b41f7b0ea481e1a7523242011-11-01T00:00:00Zhttp://www.dovepress.com/oral-fondaparinux-use-of-lipid-nanocapsules-as-nanocarriers-and-in-viv-a8700https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department, Angers University Hospital, Angers, France; 3Department of Pharmacy, Angers University Hospital, Angers, France; 4Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 5SCAHU, Animal House, Angers, FranceAbstract: Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate systems. This study examined lipid nanocapsules for their oral absorption potential as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase inversion method and cationic surfactants such as hexadecyltrimethyl ammonium bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded with Fp on their surface, were prepared and characterized (zeta potential, size and Fp association efficiency and content). In vivo studies were conducted after single oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the concentration of Fp in the plasma was measured by anti-factor Xa activity assay. The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0.2 µg/mL).Keywords: oral anticoagulant, fondaparinux, lipid nanocapsules, bioavailability, pharmacokinetics, ratsRamadan ALagarce F, Tessier-Marteau AThomas OLegras P, Macchi LSaulnier PBenoit JPDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2011, Iss default, Pp 2941-2951 (2011)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Ramadan A
Lagarce F, Tessier-Marteau A
Thomas O
Legras P, Macchi L
Saulnier P
Benoit JP
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
description Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646, Angers, France; 2Hematology Department, Angers University Hospital, Angers, France; 3Department of Pharmacy, Angers University Hospital, Angers, France; 4Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 5SCAHU, Animal House, Angers, FranceAbstract: Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate systems. This study examined lipid nanocapsules for their oral absorption potential as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase inversion method and cationic surfactants such as hexadecyltrimethyl ammonium bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded with Fp on their surface, were prepared and characterized (zeta potential, size and Fp association efficiency and content). In vivo studies were conducted after single oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the concentration of Fp in the plasma was measured by anti-factor Xa activity assay. The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0.2 µg/mL).Keywords: oral anticoagulant, fondaparinux, lipid nanocapsules, bioavailability, pharmacokinetics, rats
format article
author Ramadan A
Lagarce F, Tessier-Marteau A
Thomas O
Legras P, Macchi L
Saulnier P
Benoit JP
author_facet Ramadan A
Lagarce F, Tessier-Marteau A
Thomas O
Legras P, Macchi L
Saulnier P
Benoit JP
author_sort Ramadan A
title Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_short Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_full Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_fullStr Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_full_unstemmed Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
title_sort oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/1375d1ca280b41f7b0ea481e1a752324
work_keys_str_mv AT ramadana oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT lagarcefampnbsptessiermarteaua oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT thomaso oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT legraspampnbspmacchil oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT saulnierp oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
AT benoitjp oralfondaparinuxuseoflipidnanocapsulesasnanocarriersandinvivopharmacokineticstudy
_version_ 1718399737471696896

Ejemplares similares